Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Convertible Debt: 2020-2023

Historic Convertible Debt for Mereo BioPharma Group (MREO) over the last 3 years, with Dec 2023 value amounting to $4.4 million.

  • Mereo BioPharma Group's Convertible Debt was N/A to $4.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.4 million, marking a year-over-year change of. This contributed to the annual value of $4.4 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Mereo BioPharma Group reported Convertible Debt of $4.4 million as of FY2023, which was down 77.34% from $19.4 million recorded in FY2021.
  • In the past 5 years, Mereo BioPharma Group's Convertible Debt ranged from a high of $20.7 million in FY2020 and a low of $4.4 million during FY2023.
  • Over the past 2 years, Mereo BioPharma Group's median Convertible Debt value was $11.9 million (recorded in 2021), while the average stood at $11.9 million.
  • Data for Mereo BioPharma Group's Convertible Debt shows a maximum YoY dropped of 6.46% (in 2021) over the last 5 years.
  • Over the past 3 years, Mereo BioPharma Group's Convertible Debt (Yearly) stood at $20.7 million in 2020, then decreased by 6.46% to $19.4 million in 2021, then reached $4.4 million in 2023.